A bionic arm costs between $20,000 and $150,000, and the number moves depending on how much of the limb is missing, how many grips the hand can form, and who is signing the cheque. A body-powered hook, the technology most people picture when they think “prosthetic,” runs $3,000 to $10,000. The multi-articulating hands that show up in product launch videos, the ones with individually driven fingers and machine learning riding on top of the muscle signals, start around $50,000. The LUKE Arm, developed at DEKA with DARPA funding and brought to market by Mobius Bionics, was reported at around $100,000 when it went on sale.
Those are the sticker prices. They’re also the least interesting numbers in the file.
A prosthetic limb is not a purchase. It’s a subscription with a 40-year term. Devices wear out, residual limbs change shape, sockets stop fitting, batteries degrade, and a child’s arm has to be rebuilt every time they grow. The question that actually determines whether someone gets a working hand isn’t what the hand costs. It’s who ends up paying for the fifth one.
What You Actually Get for the Money
The jump from $10,000 to $100,000 buys one thing above all others, which is the ability to control the hand without thinking about it.
A body-powered arm works on cable tension. You shrug or extend your shoulder, a cable pulls, the hook opens. It’s a mechanical system with a real advantage that engineers tend to underrate, which is proprioceptive feedback. The user feels how hard the cable is pulling, so they know how tightly they’re gripping without looking. It’s also close to indestructible, works underwater, and never needs charging.
Myoelectric arms replace the cable with electromyography. Surface electrodes sit against the skin inside the socket and pick up the tiny voltage changes that happen when a muscle contracts. Flex the residual forearm muscles one way and the hand opens; the other way and it closes. Two electrode sites, two signals, one degree of freedom. To switch from opening the hand to rotating the wrist, the user performs a deliberate trigger, usually a hard co-contraction of both muscles, which is the software equivalent of pressing a mode button.
That mode-switching is the part nobody enjoys. Every extra function adds another layer to cycle through, so a hand with 14 grip patterns can be slower in practice than a hook with one.
The expensive tier attacks that problem directly. Pattern recognition systems, commercialised by Coapt, read signals from a ring of electrodes and use machine learning to classify the whole pattern of muscle activity rather than reacting to two isolated sites. The user trains the system by performing the movements they intend, and the classifier learns what “open hand” and “rotate wrist” look like in that particular arm. A randomised trial published in Scientific Reports in 2017 compared pattern recognition against conventional direct control in transhumeral amputees and found better scores on both the Southampton Hand Assessment Procedure (p = 0.04) and the clothespin relocation task (p = 0.02). Seven of the eight participants preferred it.
Pattern recognition works considerably better when it has better signals to read, which is where surgery enters the cost equation. Targeted muscle reinnervation reroutes the nerves that used to run to the missing hand into remaining muscle in the upper arm or chest. Those muscles then contract when the person thinks about closing their absent hand, giving the electrodes a clean, intuitive signal to work with. Research on transradial amputees published in PLOS One in 2023 found improvements across three standard hand function measures 9 to 12 months after the procedure.
So the premium isn’t really for the fingers. It’s for the interface.
Why the Sticker Price Is the Smallest Number in the File
Prosthetic limbs are consumable. Clinics generally plan on a full device replacement every three to five years, and annual maintenance and supplies typically run 5% to 10% of the device cost on top of that. Liners are consumable. Batteries degrade. Sockets need refitting whenever the residual limb changes volume, which happens with weight change, muscle atrophy, and simple ageing.
Multiply that across a working life and the arithmetic stops looking like a medical purchase and starts looking like a mortgage.
The most-cited attempt to put a figure on it comes from a cost-utility analysis by Chung and colleagues, published in Plastic and Reconstructive Surgery in 2009. Studying patients with severe open tibial fractures, the researchers calculated total average lifetime costs of $509,275 for the amputation group against $163,282 for limb salvage. The model assumed 42.8 years of remaining life, a prosthesis replacement roughly every 2.3 years, and about 17.4 devices over a lifetime.
Two caveats matter before anyone quotes that half-million figure. It describes lower-limb amputation in a trauma population, not arms. And it’s in 2009 dollars, which makes it conservative by a wide margin today. What survives inflation and study design is the shape of the problem: the device is a rounding error next to the replacement schedule.
Lifetime prosthetic cost estimator
The quote covers one device. The file covers a lifetime. Set your own assumptions below to see the difference.
Estimated lifetime cost
$240,000 – $700,000
ten myoelectric devices over 40 years at four-year intervals ($200,000 – $500,000), plus $40,000 – $200,000 in maintenance and repairs.
With no coverage, the full amount above is yours.
Device tiers are the price ranges quoted by manufacturers and prosthetic clinics in 2026. Maintenance is estimated at 5–10% of device cost per year, and the published replacement window is three to five years. Figures are estimates built from those published averages, not a quote — real costs vary by componentry, provider, plan and state. For scale, a long-running cost analysis put the average lifetime cost of an amputation at roughly $509,000 in 2007 dollars.
Who Actually Pays for a Bionic Arm
Almost nobody pays cash. The money comes from one of five places, and which one applies has more effect on the outcome than any spec on the device.
Medicare Part B treats artificial limbs as prosthetic devices and covers 80% of the approved amount once the annual deductible is met, which CMS set at $283 for 2026. The remaining 20% has no ceiling, so on a $60,000 arm the patient's share is $12,000. Medicare also requires prior authorization for six microprocessor-controlled lower-limb codes (L5856, L5857, L5858, L5973, L5980 and L5987), a process that adds weeks before anyone starts building anything.
Private insurance is where the pattern gets uglier. A KFF Health News investigation by Michelle Andrews, published in January 2025, documented denials that are hard to defend on medical grounds. Leah Kaplan, born without a left hand, was denied coverage for a $46,000 myoelectric hand. Michael Adams, who lost a leg to cancer four decades ago, was refused a $50,000 microprocessor-controlled prosthetic. The same report noted that US surgeons performed about 1.5 million knee and hip replacements in 2021, at a median price just over $68,000, without anyone questioning whether a functioning joint was medically necessary. As Jeffrey Cain, a physician and former Amputee Coalition board chair who wears two prosthetic legs, put it in that reporting, insurance covers a knee replacement if it's skin-covered but not if it's plastic.
About half of US states have passed insurance fairness laws requiring prosthetic coverage at parity with Medicare. Colorado's 2000 law was the first. The catch is that more than half of privately insured Americans are in self-insured employer plans, which state insurance law doesn't reach, so a state parity statute simply doesn't apply to them.
Then there's the route that exists when the limb loss wasn't a medical event but an incident with a responsible party. Workplace machinery without a guard, a vehicle collision, a defective product, a surgical error. In those cases the cost of the device stops being purely a coverage question and becomes a legal one, because prosthetics are a recognised category of damages in a US injury claim, alongside medical bills, lost earnings and future care. The distinction that matters is the same one insurers keep missing: a claim has to be built around the replacement schedule, not around one quote for one arm. Resources such as isBrave.com lay out how those damage categories are structured and, more usefully, how the filing deadlines vary from state to state, which is the detail that quietly ends more claims than any argument about device pricing. Most states allow two or three years, and the clock generally starts at the injury rather than at the moment someone gets a prosthetic quote.
Veterans are the outlier. VA and TRICARE coverage is broad enough that the Amputee Coalition's prevalence study excluded those populations entirely from its count, which is one reason the researchers marked their headline number with a "++".
The Access Gap Nobody Advertises
More than 5.6 million Americans live with limb loss or limb difference, according to the study the Amputee Coalition commissioned from Avalere Health and published in February 2024. That breaks down to roughly 2.3 million people with limb loss and 3.4 million with limb difference. The count is drawn from insurance claims data and excludes the uninsured along with VA and TRICARE beneficiaries, so the true figure is higher. Reporting on the study puts upper-limb cases at about 17% of amputations, with lower limbs making up the other 83%.
Here's the number that reframes everything above. Fewer than half of people with limb loss have ever been prescribed a prosthesis at all. Among Medicare beneficiaries who lost a limb in 2016, only 30% received one within three years.
Cause shapes the file as much as the total does. Most US limb loss is not traumatic, and the population skews older, with people aged 65 and over making up close to 45% of it in the same prevalence work. Traumatic amputation is the smaller share, but it arrives with an incident, an employer and frequently a machine attached, which is why the pattern behind amputations in automated factories matters to the funding question rather than only the safety one.
So the debate about whether a bionic hand should cost $60,000 or $90,000 is, for most of the population it concerns, theoretical. The binding constraint is getting any device approved.
The Control Problem That Money Cannot Solve
Buy the most expensive hand on the market and there's a meaningful chance it ends up in a drawer.
Prosthesis abandonment is one of the better-documented and less-discussed facts in the field. Biddiss and Chau's review of 25 years of literature, published in Prosthetics and Orthotics International, found mean rejection rates of 26% for body-powered and 23% for electric devices among adults, rising to 45% and 35% respectively among children. A later survey of traumatic upper-limb amputees reported 44% rejection across all amputation levels, and found no significant difference in acceptance between people amputated before or after 2006, which is a quietly damning result for two decades of product development. A 2019 international multicentre study of 174 patients came in far lower at 9%, so the honest summary is that the range is wide and depends heavily on who's counted.
The reason people give most often is not cost, weight or appearance. It's lack of function.
That finding should govern how a device gets chosen. A hand with 14 grips that requires three deliberate mode switches to pick up a coffee cup loses to a hook that does one thing instantly. Grip count is a specification. Time-to-task is the outcome, and it's the one that decides whether the arm is still being worn in year two. The psychological side of adjustment matters just as much and gets even less attention in the fitting process, which is part of why the same digital health investment that has produced companies using AI to deliver mental health support is starting to reach rehabilitation, where the drop-off after a major device change is well documented.
Osseointegration and the End of the Socket
Nearly every problem described so far traces back to one component, and it isn't electronic. It's the socket.
A socket transfers load through soft tissue that was never built to carry it. It causes pressure sores, traps sweat, slips under load, and stops fitting when the limb changes volume. Osseointegration removes it. A titanium implant is anchored directly into the bone of the residual limb and a connector passes through the skin, so the prosthesis attaches to the skeleton itself.
The OPRA Implant System from Integrum received FDA premarket approval in December 2020 and remains the only FDA-approved bone-anchored system in the United States. Approval covers transfemoral amputees from trauma or cancer, and those who can't tolerate a conventional socket because of recurrent skin breakdown, pain, sweating or a residual limb too short to hold a socket. In the approval data, prosthetic use scores improved by 35.1 points on a 100-point scale at two years and 39.6 points at five, measured against the same patients' scores with a socket.
The economics look better than the surgery's reputation suggests. A Markov model published in Bone & Joint Open put the lifetime incremental cost-effectiveness ratio at $279 per quality-adjusted life-year for treatment-naive patients and $273 for those who had already failed with a socket. For context, health economists routinely treat interventions under $50,000 per QALY as good value. Bone-anchored limbs are two orders of magnitude below that line.
Which raises an obvious question about why access remains so narrow, and the answer has more to do with surgical capacity and payer caution than with arithmetic.
How to Read a Prosthetic Quote Before Signing
A quote for an upper-limb prosthesis is not a price tag. It's a bundle of billing codes, and the codes determine what happens when something breaks in year three.
The last one is the question most people never think to ask, and it’s the one that predicts the outcome of an appeal. Is your plan fully insured, or is your employer self-insuring and simply renting the insurer’s name and network? Ask the HR department, not the insurer. It’s a two-minute conversation, and it tells you which rulebook your claim will actually be judged under.
On the policy side, the pressure is building from the states. The So Every BODY Can Move campaign, which pushes for coverage of activity-specific prosthetics and orthotics rather than one device for all of life, has moved laws in 15 states so far against a target of 28 by 2028, with a large slate of bills filed in 2026.
Frequently Asked Questions
How much does a bionic arm cost in 2026
Between $20,000 and $150,000 for powered devices, with multi-articulating bionic hands generally starting around $50,000 and the LUKE Arm reported at around $100,000 at launch. Body-powered arms cost $3,000 to $10,000. Price varies with amputation level, since a device that has to replace an elbow and a wrist costs substantially more than one replacing a hand.
Does insurance cover a bionic arm
Often partially, and denials for advanced devices are common. About half of US states require prosthetic coverage at parity with Medicare, but those laws don't apply to self-insured employer plans, which cover more than half of privately insured Americans. Insurers frequently approve a basic device while refusing a myoelectric or microprocessor-controlled one on medical necessity grounds. If that happens, the denial letter is the document to read closely, because the stated reason sets the ground for the appeal.
Does Medicare pay for a prosthetic arm
Yes. Medicare Part B covers artificial limbs at 80% of the approved amount once the annual deductible is met, set at $283 for 2026. The patient's 20% coinsurance has no upper limit, which on a $60,000 device means $12,000 out of pocket before any supplemental coverage.
How long does a prosthetic arm last
Three to five years for a full device, with sockets often needing replacement sooner as the residual limb changes shape. Annual maintenance and consumables typically add 5% to 10% of the device cost. Children need rebuilds far more frequently because they grow. Plan the budget around the cycle, not the purchase.
Why do people stop using their prosthetic arms
Lack of function is the reason given most often in the research, ahead of cost, weight or appearance. Published adult rejection rates cluster around 23% to 26% in older reviews, with some studies of traumatic amputees reporting figures as high as 44%. Devices that take several deliberate mode switches to complete a simple task get abandoned faster than simpler ones.
Can you get a bionic hand if you were born without one
Yes, congenital limb difference is a standard indication for myoelectric and multi-grip devices. Coverage is a different matter. KFF Health News documented the case of a woman born without a left hand who was denied a $46,000 myoelectric hand by her insurer. Roughly 3.4 million Americans live with limb difference rather than limb loss.
What is the difference between myoelectric and bionic
Myoelectric describes the control method, meaning the device reads electrical signals from muscle. Bionic is a marketing term, generally used for multi-articulating myoelectric hands with individually powered fingers and multiple programmable grips. Every bionic hand on the market is myoelectric; not every myoelectric hand is sold as bionic.
The Real Cost Question
Prosthetics is one of the few areas of consumer technology where the engineering has outrun the payment system by a decade. Pattern recognition, nerve rerouting and bone-anchored implants all work, all have published outcome data behind them, and all remain out of reach for a population where fewer than half have ever been prescribed any device at all.
The useful way to evaluate a bionic arm isn't by grip count or by the number on the quote. It's by asking what the next 20 years of that file looks like, who is contractually on the hook for each replacement, and whether anyone has counted them properly. Get that answer in writing before the first fitting.
